SEC Tracker
Get the app

Inovio Pharmaceuticals INO

Inovio Pharmaceuticals reported a net loss of $49.21 million

Inovio Pharmaceuticals (INO) filed a 10-Q with the SEC on Nov 10, 2026, 4:02 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue for Q3 2026 was $298,901
  2. Diluted EPS was -$0.50 for Q3 2026
  3. Cash and equivalents were $46.96 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Inovio Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.